Danish multinational pharmaceutical company focused exclusively on neuroscience, with research facilities in Denmark and the United States and production in Denmark, France and Italy. Lundbeck Portugal — Produtos Farmacêuticos, Unipessoal Lda. operates from the Quinta da Fonte Office Park in Paço de Arcos, Oeiras, distributing the group's depression, schizophrenia and migraine portfolio to Portuguese hospitals and pharmacies.
Lundbeck Portugal — Produtos Farmacêuticos, Unipessoal Lda. is the wholly-owned Portuguese affiliate of H. Lundbeck A/S, a Copenhagen-listed neuroscience-focused pharmaceutical group. The Portuguese unit operates from the Quinta da Fonte Office Park in Paço de Arcos (Oeiras) — one of Greater Lisbon's largest pharmaceutical clusters, alongside Bayer, GSK and Janssen affiliates — with a small commercial team supporting Portuguese hospital, public-sector and pharmacy channels.
The local portfolio is strategically aligned with Lundbeck's global focus on brain health, covering depression, migraine and schizophrenia treatments. The unit is integrated into the group's European commercial structure and reports up into Lundbeck's broader EMEA organisation, contributing to the parent group's global revenues. Group-wide, Lundbeck's research is concentrated in Denmark and the United States, with production facilities in Denmark, France and Italy.
Lundbeck is one of the most consistent Danish industrial presences in Portugal's pharmaceutical sector, illustrating the broader pattern of Nordic specialty-pharma companies using Lisbon as a Southern European commercial hub rather than a manufacturing base. For Portuguese clinicians, Lundbeck provides direct access to a global neuroscience pipeline; for Danish corporate watchers, the Portuguese entity is part of a stable European base that supports Lundbeck's positioning as a pure-play neuroscience operator.
Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.
Talk to Fractio →